The inability of the BIM deletion to segregate poor versus good risk patients was somewhat surprising given previous reports describing the ability of in vitro as well as clinical GC responses to predict long-term outcomes in pediatric ALL [33]–[37]. The gene discussed is BCL2L11; the disease is acute lymphoblastic leukemia.